Modeling Prion-Like Processing of Tau Protein in Alzheimer’s Disease for Pharmaceutical Development

Autor: Damon Wischik, Björn Schelter, Charles R. Harrington, John Storey, Claude M. Wischik

Publikováno v: Journal of Alzheimer's Disease

Following our discovery of a fragment from the repeat domain of tau protein as a structural constituent of the PHF-core in Alzheimer’s disease (AD), we developed an assay that captured several key features of the aggregation process. Tau-tau bindin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c17dd48ff499dec00a0c6da40dfcad1e
https://doi.org/10.3233/jad-170727

Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease

Autor: Claude M. Wischik, Christopher Paul Larch, Charles R. Harrington, Scott Clunas, Janet Elizabeth Rickard, Colin Marshall, Steven Kemp, John Storey, James Peter Sinclair, Michael Simpson, Ishaq Ahtsham, Sarah L. Nicoll, Lynda Jane Storey, Kathleen A. Harrington, David Horsley

Publikováno v: The Journal of Biological Chemistry

Background: Tau aggregation inhibitors could treat Alzheimer disease. Results: Stable reduced forms of leucomethylthioninium (LMTX®) are active in blocking prion-like Tau aggregation in novel cellular models. Conclusion: The intracellular Ki (0.12 �

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96ee7a7ecc0364ee58507a632357ab54
https://doi.org/10.1074/jbc.m114.616029

Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.

Autor: Harrington CR; From the School of Medicine and Dentistry, University of Aberdeen, Aberdeen AB25 2ZP, United Kingdom, TauRx Therapeutics Ltd., Singapore 068805, and the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom c.harrington@abdn.ac.uk., Storey JM; TauRx Therapeutics Ltd., Singapore 068805, and the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom., Clunas S; the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom., Harrington KA; From the School of Medicine and Dentistry, University of Aberdeen, Aberdeen AB25 2ZP, United Kingdom., Horsley D; From the School of Medicine and Dentistry, University of Aberdeen, Aberdeen AB25 2ZP, United Kingdom., Ishaq A; the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom., Kemp SJ; the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom., Larch CP; the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom., Marshall C; the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom., Nicoll SL; the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom., Rickard JE; From the School of Medicine and Dentistry, University of Aberdeen, Aberdeen AB25 2ZP, United Kingdom., Simpson M; the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom., Sinclair JP; the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom., Storey LJ; the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom., Wischik CM; From the School of Medicine and Dentistry, University of Aberdeen, Aberdeen AB25 2ZP, United Kingdom, TauRx Therapeutics Ltd., Singapore 068805, and cmw@taurx.com.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2015 Apr 24; Vol. 290 (17), pp. 10862-75. Date of Electronic Publication: 2015 Mar 10.